Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

May 01, 2023; Volume 103,Issue 5

Minireview

  • Aryl Hydrocarbon Receptor as a Therapeutical Target of Environmentally Induced Skin Conditions
    You have access
    Aryl Hydrocarbon Receptor as a Therapeutical Target of Environmentally Induced Skin Conditions
    Caroline de Almeida Freitas Accioli, Michelle Sabrina da Silva, Bianca Aloise Maneira Corrêa Santos and Carlos Rangel Rodrigues
    Molecular Pharmacology May 2023, 103 (5) 255-265; DOI: https://doi.org/10.1124/molpharm.122.000627

Articles

  • Alkannin Attenuates Amyloid <em>β</em> Aggregation and Alzheimer’s Disease Pathology
    You have access
    Alkannin Attenuates Amyloid β Aggregation and Alzheimer’s Disease Pathology
    Toru Hosoi, Kyosuke Yazawa, Michihiro Imada, Akari Tawara, Chihiro Tohda, Yasuyuki Nomura and Koichiro Ozawa
    Molecular Pharmacology May 2023, 103 (5) 266-273; DOI: https://doi.org/10.1124/molpharm.121.000468
  • Application of Mixed-Solvent Molecular Dynamics Simulations for Prediction of Allosteric Sites on G Protein–Coupled Receptors
    You have access
    Application of Mixed-Solvent Molecular Dynamics Simulations for Prediction of Allosteric Sites on G Protein–Coupled Receptors
    Wallace K.B. Chan, Heather A. Carlson and John R. Traynor
    Molecular Pharmacology May 2023, 103 (5) 274-285; DOI: https://doi.org/10.1124/molpharm.122.000612
  • You have access
    BAY58-2667 Activates Different Soluble Guanylyl Cyclase Species by Distinct Mechanisms that Indicate Its Principal Target in Cells is the Heme-Free Soluble Guanylyl Cyclase-Heat Shock Protein 90 Complex
    Yue Dai and Dennis J. Stuehr
    Molecular Pharmacology May 2023, 103 (5) 286-296; DOI: https://doi.org/10.1124/molpharm.122.000624

Erratum

  • You have access
    Correction to “A Novel Semisynthetic Inhibitor of the FRB Domain of Mammalian Target of Rapamycin Blocks Proliferation and Triggers Apoptosis in Chemoresistant Prostate Cancer Cells”
    Molecular Pharmacology May 2023, 103 (5) 297; DOI: https://doi.org/10.1124/mol.112.081349err
  • You have access
    Correction to “The Common LncRNAs of Neuroinflammation-Related Diseases”
    Molecular Pharmacology May 2023, 103 (5) 298; DOI: https://doi.org/10.1124/molpharm.122.000530err
Back to top
PreviousNext

In this issue

Molecular Pharmacology: 103 (5)
Molecular Pharmacology
Vol. 103, Issue 5
1 May 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts

Jump to

  • Minireview
  • Articles
  • Erratum
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics